255 related articles for article (PubMed ID: 17214849)
1. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
[TBL] [Abstract][Full Text] [Related]
2. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
Yoon HS; Youn JI
J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
[TBL] [Abstract][Full Text] [Related]
3. Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis.
Hirano T; Oka K; Umezawa Y; Hirata M; Oh-i T; Koga M
Clin Pharmacol Ther; 1998 Apr; 63(4):465-70. PubMed ID: 9585801
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
[TBL] [Abstract][Full Text] [Related]
5. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)].
Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F
Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920
[TBL] [Abstract][Full Text] [Related]
6. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with the use of cyclosporin A in psoriasis. Results of a retrospective study.
Ojeda R; Sánchez Regaña M; Massana J; Oliete R; Umbert P
J Dermatolog Treat; 2005; 16(4):238-41. PubMed ID: 16249146
[TBL] [Abstract][Full Text] [Related]
8. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.
Smit JV; de Jong EM; van Hooijdonk CA; Otero ME; Boezeman JB; van de Kerkhof PC
J Am Acad Dermatol; 2004 Aug; 51(2):257-64. PubMed ID: 15280845
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.
Schopf RE; Hultsch T; Lotz J; Bräutigam M
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):234-9. PubMed ID: 9883435
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of histopathological and immunohistochemical findings in skin biopsies from patients with psoriasis before and after treatment with acitretin.
Werner B; Bresch M; Brenner FM; Lima HC
J Cutan Pathol; 2008 Mar; 35(3):302-10. PubMed ID: 18251745
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
Flytström I; Stenberg B; Svensson A; Bergbrant IM
Br J Dermatol; 2008 Jan; 158(1):116-21. PubMed ID: 17986302
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.
Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U
Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388
[TBL] [Abstract][Full Text] [Related]
15. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
Peluso AM; Bardazzi F; Tosti A; Varotti C
Acta Derm Venereol Suppl (Stockh); 1994; 186():90-1. PubMed ID: 8073851
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunohistochemical evaluation of psoriatic plaques treated with topical 5-aminolaevulinic acid photodynamic therapy.
Fransson J; Ros AM
Photodermatol Photoimmunol Photomed; 2005 Dec; 21(6):326-32. PubMed ID: 16313245
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ
Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
[TBL] [Abstract][Full Text] [Related]
18. Synchronous balneophototherapy is effective for the different clinical types of psoriasis.
Holló P; Gonzalez R; Kása M; Horváth A
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):578-81. PubMed ID: 16164712
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris.
Abe M; Ishibuchi H; Syuto T; Sogabe Y; Yokoyama Y; Ishikawa O
J Dermatol; 2007 May; 34(5):290-3. PubMed ID: 17408436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]